CENTANNI, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 83
AS - Asia 69
EU - Europa 37
SA - Sud America 19
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 210
Nazione #
US - Stati Uniti d'America 78
SG - Singapore 41
IT - Italia 23
BR - Brasile 15
CN - Cina 13
GB - Regno Unito 6
VN - Vietnam 5
DE - Germania 3
HK - Hong Kong 3
MX - Messico 3
AR - Argentina 2
BD - Bangladesh 2
CA - Canada 2
LT - Lituania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
EC - Ecuador 1
FI - Finlandia 1
IQ - Iraq 1
JP - Giappone 1
MA - Marocco 1
NL - Olanda 1
PK - Pakistan 1
PL - Polonia 1
UY - Uruguay 1
Totale 210
Città #
Singapore 28
Hefei 13
Santa Clara 11
Milan 8
Dallas 7
Ashburn 4
New York 4
Chicago 3
Hong Kong 3
Lawrence 3
Muggiò 3
Munich 3
Princeton 3
Rome 3
San Francisco 3
Assago 2
Atlanta 2
Brooklyn 2
Campobasso 2
Charlotte 2
Des Moines 2
Ho Chi Minh City 2
London 2
Palermo 2
San Nicola Manfredi 2
São Paulo 2
Baku 1
Boa Vista 1
Boydton 1
Bắc Ninh 1
Carandaí 1
Cincinnati 1
Corpus Christi 1
Corrientes 1
Cuauhtémoc 1
Curitiba 1
Dubai 1
Fortaleza 1
Hanoi 1
Harrisburg 1
Hermoso Campo 1
Itanhém 1
Itapevi 1
Legnago 1
Los Angeles 1
Maldonado 1
Mesquite 1
Mexico City 1
Montreal 1
Ninh Bình 1
Norwalk 1
Nova Iguaçu 1
Passo Fundo 1
Philadelphia 1
Phoenix 1
Portão 1
Preston 1
Quito 1
Raleigh 1
Rhyl 1
Salé 1
Seattle 1
Soledade 1
São José 1
São Pedro 1
The Dalles 1
Tokyo 1
Três Pontas 1
Turku 1
Warsaw 1
Wilmington 1
Totale 166
Nome #
Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis 23
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study 23
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry 23
Point-of-Care Lung Sonography: An Audit of 1150 Examinations 19
ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study 19
Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis 18
Profiling severe asthma: Any relevance for age? An analysis from Severe Asthma Network Italy (SANI) cohort 18
Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19? 16
Durability of benralizumab effectiveness in severe eosinophilic asthma patients with and without chronic rhinosinusitis with nasal polyps: a post hoc analysis from the ANANKE study 15
Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study 14
Lung Ultrasound B Lines: Etiologies and Evolution with Age 13
Sustained Effectiveness of Benralizumab in Naïve and Biologics-Experienced Severe Eosinophilic Asthma Patients: Results from the ANANKE Study 12
COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments 12
Totale 225
Categoria #
all - tutte 3.463
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.463


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20228 0 0 0 0 0 0 2 2 0 1 3 0
2022/202310 6 0 0 1 1 1 0 1 0 0 0 0
2023/202425 5 1 3 0 0 5 1 2 0 3 5 0
2024/202588 16 2 3 1 2 13 14 5 1 2 17 12
2025/202691 34 32 22 3 0 0 0 0 0 0 0 0
Totale 225